Viking Therapeutics Launches Phase-1 Study with VK3019 – Analysts Set Price Target at $93.60 USD

Viking Therapeutics announced on June 24, 2026 the start of a Phase-1 study for the drug candidate VK3019. VK3019 is a dual agonist targeting amylin and calcitonin receptors and is being developed for the treatment of obesity. The San Diego-based company is thereby expanding its pipeline in the growing market for obesity therapies.

VK3019: A New Approach in the Obesity Market

The drug candidate VK3019 pursues a dual mechanism of action by activating both amylin and calcitonin receptors. These receptors play a central role in regulating appetite and satiety. The Phase-1 study serves to examine the safety, tolerability, and pharmacokinetics of the drug in healthy volunteers – a standard first step in the clinical development of new medicines.

With this development, Viking Therapeutics is positioning itself in a market segment that has experienced strong growth in recent years. Other companies such as Novo Nordisk and Eli Lilly have already achieved commercial success with GLP-1-based drugs. Viking's approach differs through its focus on amylin and calcitonin receptors.

Existing Pipeline: VK2809 and Other Candidates

In addition to VK3019, Viking Therapeutics' pipeline includes several other drug candidates. VK2809, an oral, selective agonist of the thyroid hormone receptor beta (TRβ), is in Phase-IIb studies. The company is testing VK2809 for both non-alcoholic steatohepatitis (NASH) – an advanced form of fatty liver disease – and non-alcoholic fatty liver disease (NAFLD).

VK5211, an orally available, non-steroidal selective androgen receptor modulator (SARM), is undergoing Phase-II studies for patients recovering from non-elective hip fractures. Additionally, Viking is planning the development of VK0612, an oral candidate for type 2 diabetes, which is expected to enter Phase-IIb studies.

Stock Price and Technical Indicators

On July 2, 2026, Viking Therapeutics' stock closed at $32.85 USD, up 0.15 percent compared to the previous day ($32.80 USD). Trading volume was 10,577 shares. The Relative Strength Index (RSI) stood at 65.03 points on July 1, 2026, after reaching values above 75 at the end of June. An RSI above 70 is technically considered overbought, below 30 as oversold.

According to analyst estimates from July 2, 2026, the mean price target is $93.60 USD, the median price target is $95.00 USD. The range extends from $83.00 USD (lower target) to $101.00 USD (upper target). Of 24 analysts, 23 rate the stock as "Buy" or "Strong Buy," with only one analyst recommending "Hold." No sell recommendations are present.

Market Environment and Competition

The market for obesity therapies has experienced dynamic development in recent years. The approval and commercial success of GLP-1 receptor agonists have increased interest from investors and pharmaceutical companies. With its amylin and calcitonin approach, Viking Therapeutics is pursuing an alternative mechanism of action, whose clinical efficacy and tolerability still need to be demonstrated in early study phases.

The company's valuation reflects expectations for its pipeline. With a market capitalization based on the current price of $32.85 USD, the market is pricing in the opportunities and risks of clinical development. The analyst consensus estimate of $93.60 USD implies an upside potential of around 185 percent compared to the current price – an indicator of the financial community's positive assessment of the pipeline projects.

Outlook and Next Steps

The Phase-1 study of VK3019 represents the first step in the clinical development of this drug candidate. Results from this early study phase are typically expected within six to twelve months, depending on study design and patient recruitment. Positive data could pave the way for Phase-2 studies, in which efficacy and dosing would be tested in patients with obesity.

Clinical milestones also lie ahead for VK2809 and the other pipeline candidates. The development of medicines for NASH and NAFLD is considered challenging, as regulatory requirements are high and only a few therapies have been approved so far. Viking Therapeutics must demonstrate both efficacy and safety in the ongoing studies in order to hold its own in the competitive environment.

Investors in the DACH region who are monitoring Viking Therapeutics should note that the stock is listed in USD and currency fluctuations play a role. The high analyst rating and broad price target range highlight the potential, but also the uncertainty associated with biotechnology companies in early development stages.